Search

everythinglearnresearchcommunity

for

Search:↓

A user experienced increased hair shedding after taking pumpkin seed oil for 4 weeks and is unsure if it's a "dread shed" or if the oil isn't suitable. They cannot tolerate anti-androgens like spironolactone and finasteride due to side effects and are seeking advice on whether to continue with pumpkin seed oil.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

Hair transplants, oral finasteride, oral minoxidil, and dutasteride mesotherapy are highly effective for treating AGA hair loss. This combination can maintain and improve hair for most people, except those with very aggressive AGA.

The user is experiencing severe hair loss and color change despite low testosterone levels and healthy lifestyle changes. They have tried ketoconazole shampoo and consulted a dermatologist, who found no scalp issues but suggested using Toppik for coverage.

Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

A user is treating hair loss with Dutasteride, Minoxidil, RU58841, Derminator 2, Vitamin D, Biotin, and Zinc. After 6 months, there's no significant visual improvement, but the user feels less insecure about Retrograde Alopecia.

Amino acids like lysine, methionine, and cysteine may help with androgenetic alopecia when taken in high doses along with a DHT blocker. Users discuss combining these with treatments like Minoxidil, finasteride, and RU58841.

The user is experiencing severe hair loss, possibly due to telogen effluvium, after stress, poor nutrition, and hormonal changes. They are using Nizoral and supplements but are considering hormonal treatments like spironolactone despite previous side effects.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

A woman experiencing hair loss and facial hair growth suspects PCOS or androgenic alopecia and is considering treatments like Rogaine, but is concerned about the cost. She has tried various hair care methods and is awaiting a hormone doctor appointment, while others suggest she may have a hormonal imbalance and recommend seeing a gynecologist or trying cheaper versions of Rogaine.

Hair loss treatments discussed include microneedling, minoxidil, tretinoin, finasteride, dutasteride, pumpkin seeds, saw palmetto, and scalp massage. The consensus is that finasteride or dutasteride is necessary for significant regrowth, while other methods may only slow hair loss.

A user reported full recovery from Post Finasteride Syndrome after 6 months of HCG treatment. They used 250IU of HCG three times a week.

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.

Glycine may upregulate 5AR, potentially affecting hair. Users suggest using Finasteride to manage hair loss concerns.

The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.

The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.

The user is experiencing worsening hair loss despite undergoing monthly injectable finasteride, clay masks, laser therapy, and microneedling. They are concerned about severe shedding in areas not typically affected by male pattern baldness and are considering seeking a second opinion.

The user is experiencing significant hair thinning on the front scalp while taking oral finasteride and minoxidil. They are unsure if it's androgenetic alopecia or related to seborrheic dermatitis.

Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

The conversation discusses using GHK-Cu for hair loss, with one user suggesting subcutaneous administration for better control. The effectiveness of topical application is questioned due to a lack of reliable reviews.